HRAS oncogenic function is dependent on farnesylation and has been shown to be inhibited by tipifarnib, a selective inhibitor of farnesyltransferase, in HRAS mutant (mHRAS) HNSCC xenograft models [79]. Here, HRAS is linked to head and neck squamous cell carcinoma.